{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=34&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Orlando",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 6846,
    "total_pages": 685,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=35&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=33&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T04:38:49.636Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05547165",
      "title": "Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ductus Arteriosus, Patent"
      ],
      "interventions": [
        {
          "name": "Percutaneous Patent Ductus Arteriosus Closure (PPC)",
          "type": "DEVICE"
        },
        {
          "name": "Responsive Management Intervention",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Echocardiogram, cardiac",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "COMBINATION_PRODUCT",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "32 Days",
        "sex": "ALL",
        "summary": "7 Days to 32 Days"
      },
      "enrollment_count": 240,
      "start_date": "2023-02-21",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05547165"
    },
    {
      "nct_id": "NCT04622007",
      "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tomivosertib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Effector Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2021-06-02",
      "completion_date": "2024-12-09",
      "has_results": false,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 131,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04622007"
    },
    {
      "nct_id": "NCT01272037",
      "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Ductal Carcinoma In Situ",
        "Invasive Breast Carcinoma",
        "Multicentric Breast Carcinoma",
        "Multifocal Breast Carcinoma",
        "Synchronous Bilateral Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Systemic Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5018,
      "start_date": "2011-02-28",
      "completion_date": "2027-01-08",
      "has_results": true,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 1435,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272037"
    },
    {
      "nct_id": "NCT03784079",
      "title": "A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3640254",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching GSK3640254 Mesylate salt",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-01-31",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 2,
      "location_summary": "Bakersfield, California • Orlando, Florida",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03784079"
    },
    {
      "nct_id": "NCT03882762",
      "title": "A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetic"
      ],
      "interventions": [
        {
          "name": "Cebranopadol 200 μg tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2013-06-20",
      "completion_date": "2014-09-17",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03882762"
    },
    {
      "nct_id": "NCT02477670",
      "title": "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "AVP-786",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 145,
      "start_date": "2015-09-01",
      "completion_date": "2017-07-21",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 17,
      "location_summary": "Cerritos, California • Garden Grove, California • National City, California + 14 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477670"
    },
    {
      "nct_id": "NCT02135302",
      "title": "A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Impaired Hepatic Function"
      ],
      "interventions": [
        {
          "name": "eravacycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tetraphase Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-10",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2021-12-17",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 3,
      "location_summary": "Lakewood, Colorado • Orlando, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02135302"
    },
    {
      "nct_id": "NCT00739739",
      "title": "An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis",
        "Painful Bladder Syndrome"
      ],
      "interventions": [
        {
          "name": "PD 0299685 at 15mg BID",
          "type": "DRUG"
        },
        {
          "name": "PD 0299685 at 30mg BID",
          "type": "DRUG"
        },
        {
          "name": "placebo for PD 0299685",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2008-08",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-28",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 23,
      "location_summary": "Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendora",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00739739"
    },
    {
      "nct_id": "NCT02258542",
      "title": "A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 2133,
      "start_date": "2014-11-19",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 100,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Scottsboro, Alabama + 80 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258542"
    },
    {
      "nct_id": "NCT05011305",
      "title": "Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis",
        "Fibrosis"
      ],
      "interventions": [
        {
          "name": "Saroglitazar Magnesium 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Saroglitazar Magnesium 4 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zydus Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 189,
      "start_date": "2021-08-18",
      "completion_date": "2025-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-01T04:38:49.636Z",
      "location_count": 101,
      "location_summary": "Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 75 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05011305"
    }
  ]
}